Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30732662 | 0.94 | MEN1 (0.42) | MEN1KMT2AYAP1HTTNPC1 | |
| SCHEMBL607180 | 0.90 | MEN1 (0.46) | MEN1KMT2AYAP1HTTTACR1 | |
| SCHEMBL607947 | 0.89 | TACR1 (0.47) | MEN1KMT2AYAP1TACR1OPRD1 | |
| SCHEMBL17609000 | 0.89 | OPRD1 (0.47) | MEN1KMT2AYAP1NPC1RAB9A | |
| SCHEMBL2793178 | 0.89 | OPRD1 (0.47) | MEN1KMT2AYAP1HTTTACR1 | |
| SCHEMBL6083618 | 0.89 | EGLN2 (0.50) | MEN1KMT2AYAP1TACR1OPRD1 | |
| SCHEMBL16825735 | 0.88 | MEN1 (0.45) | MEN1KMT2AYAP1HTTTACR1 | |
| SCHEMBL16825914 | 0.87 | OPRD1 (0.45) | MEN1KMT2AYAP1TACR1OPRD1 | |
| SCHEMBL24940830 | 0.86 | MEN1 (0.43) | MEN1KMT2AYAP1TACR1OPRD1 | |
| SCHEMBL17608882 | 0.86 | P2RX7 (0.44) | MEN1KMT2AYAP1TACR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| EP-2231687-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | Sun Pharma Advanced Research Company Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | MEN1 4323/4885KMT2A 2717/4885YAP1 1009/4885 |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | MEN1 2135/4885KMT2A 1249/4885YAP1 177/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | MEN1 2246/4885KMT2A 1377/4885YAP1 351/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | MEN1 2354/4885KMT2A 1395/4885YAP1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.